ERBB2 and breast carcinoma: Studies in mouse models of breast cancer have shown that intratumoral administration of ADU-S100 (an analog of c-di-AMP) alone was able to induce durable tumour clearance in 100% of parental FVB/N mice that are able to mount potent immune responses to the implanted neu-positive tumour cells, but the treatment only resulted in tumour clearance in 10% of the FVB/N-derived neu/N transgenic mice that have well-established peripheral immune tolerance to the endogenous neu antigen [76,81].